Motility improvement (increase) by 1 class or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes motility improvement (increase) by 1 class or more compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
Quality of life improvement by at least 6 points · thyroid‐associated ophthalmopathy
1 finding from 1 review
Adverse events · thyroid‐associated ophthalmopathy
Summary of findings table ‐ Rituximab showed no clear difference in adverse events compared with intravenous methylprednisolone (low certainty).
1 finding from 1 review
Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
It is very uncertain whether cyclosporin changes disease‐specific mortality (time to compared with intravenous immunoglobulin (IVIG) (very low certainty).
1 finding from 1 review
Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
MRONJ (incidence proportion) · People with cancer treated with intravenous bisphosphonates undergoing dental extractions (at risk of MRONJ)
It is very uncertain whether dental extraction protocol with plasma rich in growth factors (PRGF)… changes MRONJ (incidence proportion) compared with standard dental extraction protocol without PRGF (very low certainty).
1 finding from 1 review
MRONJ (incidence rate: cases per patient-year) · Men with metastatic prostate cancer receiving intravenous zoledronic acid (at risk of MRONJ)
It is very uncertain whether dental examinations at three-month intervals and preventive treatments changes MRONJ (incidence rate: cases per patient-year) compared with standard care (very low certainty).
1 finding from 1 review
30‐Day amputation‐free survival · patients with < 30 days' limb ischaemiaa
It is very uncertain whether intra‐arterial delivery changes 30‐Day amputation‐free survival compared with intravenous delivery (very low certainty).
1 finding from 1 review
Amputation · patients with < 30 days' limb ischaemiaa
1 finding from 1 review
30‐Day mortality · patients with < 30 days' limb ischaemiaa
1 finding from 1 review
Vessel patency ‐ radiological success ‐ complete (to end of treatment) · patients with < 30 days' limb ischaemiaa
Intra‐arterial delivery may leads to higher vessel patency ‐ radiological success ‐ complete (to end of treatment) compared with intravenous delivery (low certainty).
1 finding from 1 review
Duration of thrombolysis (to end of treatment) · patients with < 30 days' limb ischaemiaa
1 finding from 1 review